You are here

  • Home
  • Archive
  • Volume 63, Issue 7
  • Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD

Article Text

Article menu

Download PDFPDF

Chronic obstructive pulmonary disease
Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD
Free
  1. D Singh1,
  2. J Brooks2,
  3. G Hagan3,
  4. A Cahn4,
  5. B J O’Connor5
  1. 1Medicines Evaluation Unit, University Hospital of South Manchester/University of Manchester, Manchester, UK
  2. 2Statistics and Programming, GlaxoSmithKline R&D, Greenford, UK
  3. 3Respiratory MDC, GlaxoSmithKline R&D, Greenford, UK
  4. 4Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline R&D, Greenford, UK
  5. 5Department of Respiratory Medicine and Allergy, Guy’s, King’s and St Thomas’ School of Medicine, London, UK
  1. Dr D Singh, Medicines Evaluation Unit, University Hospital of South Manchester, Manchester M33 3TR, UK; dsingh{at}meu.org.uk

Abstract

Background: The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but there are few data on their effectiveness when used together. We compared the effects of SFC 50/500 μg twice daily in addition to TIO 18 μg once daily with the individual treatments alone.

Methods: 41 patients with COPD participated in a randomised, double blind, double dummy, three way crossover study with 2 week washout periods between treatments. Lung function assessment included plethysmography and spirometry. The primary end point was post-dose specific airways conductance (sGaw) area under the curve (AUC0–4 h) on day 14.

Results: AUC0–4 h sGaw was significantly higher on day 14 after SFC+TIO compared with TIO (22%) or SFC alone (27%) (both p<0.001). SFC+TIO significantly improved trough forced expiratory volume in 1 s compared with TIO alone (212 ml, p<0.001) and SFC alone (110 ml, p = 0.017) on day 14. Inspiratory capacity measurements also showed significant benefits for triple therapy over individual components on day 14. Subjects receiving SFC+TIO had clinically relevant improvements in Transition Dyspnoea Index (TDI) total score of 2.2 compared with TIO alone (p<0.001) (but not SFC alone, 0.7; NS) and used significantly less rescue medication (1.0 occasion less daily than TIO (p<0.001) and 0.6 less than SFC (p = 0.01)).

Conclusion: SFC+TIO triple therapy led to greater improvements in bronchodilation compared with TIO and SFC alone. The advantages of triple therapy are observed across a range of physiologically important parameters, including airway conductance and lung volumes. Triple therapy also led to patient related benefits by improving TDI and use of rescue medication.

Trial registration number: NCT00325169.

https://doi.org/10.1136/thx.2007.087213

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: The study was funded by an unrestricted research grant from GlaxoSmithKline.

    • Competing interests: None.

    • Ethics approval: The study protocol was approved by the appropriate institutional review boards and conducted in accordance with good clinical practice guidelines and the 1996 version of the Declaration of Helsinki (study No SCO104962).

    • Note from Editor-in-Chief: J A Wedzicha recruited patients to this study but was not involved in data analysis or preparation of the manuscript and was not the handling editor of this paper.